Project Grant R01HL185859
Award Date 7/15/26
Completion Date 3/31/30
Dollars Obligated $1.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital a $739,474 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) on August 18, 2025, to investigate the anti-fibrotic roles of stress-induced tRNA-derived small RNAs (tDRs) in cardiac fibrosis. The research will be conducted through May 31, 2030, and focuses on characterizing the mechanisms by which ASP-GTC-3' tDR, a regulatory RNA fragment derived from transfer RNA,...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Tufts University School of Medicine a $1.12 million Project Grant (CFDA 93.837, Cardiovascular Diseases Research) on September 17, 2025, to conduct a multiethnic and multiomics analysis of longitudinal changes in DNA methylation (DNAM) and cardiovascular health. The four-year research initiative, concluding July 31, 2029, integrates longitudinal epigenome-wide DNAM data with behavioral, clinical, genetic,...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Harvard College's Office for Sponsored Programs a Project Grant of $151,040 on February 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The research will be conducted in Massachusetts and is expected to conclude by November 30, 2028. This award funds investigative research into the role of Tolloid (TLD) proteases in atrial fibrosis pathogenesis, specifically examining how TLD...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The University of Texas Southwestern Medical Center a $1.62 million Project Grant on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate circulating metabolites underlying cardiometabolic risk for cardiac dysfunction and heart failure in diverse populations. The research employs metabolomics and genomics to identify biologic pathways linking metabolic...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Johns Hopkins University a Project Grant totaling $638,176 effective May 1, 2026, through February 28, 2029, under the Cardiovascular Diseases Research program (CFDA 93.837). This grant funds basic and translational research investigating thrombospondin-1 (TSP-1), a matricellular protein implicated in cardiac fibrosis associated with heart failure with preserved ejection fraction (HFpEF). The research...
- Federal Project Grant Award Summary Massachusetts General Hospital's Research Management Division received a $867,656 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on May 1, 2026, with a completion date of February 28, 2031. The award funds research to determine the effectiveness of guideline-directed medical therapies (GDMT) for heart failure with mildly reduced ejection fraction (HFmrEF)—a...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $811,885 to the J. David Gladstone Institutes under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025. The award funds research to elucidate epigenomic mechanisms of cardiac fibrosis and heart failure pathogenesis, with a completion date of May 31, 2029. The research leverages novel genetic mouse models, advanced transcriptional and epigenomic...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Massachusetts a $425,971 Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) effective July 6, 2026, through June 30, 2028, to develop a biomaterials-integrated microphysiological bone marrow chip model. The project aims to create a physiologically relevant preclinical system that recapitulates the structural and functional interdependence of bone and bone marrow...
- Federal Project Grant Award Summary The University of Arizona received a $562,733 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 6, 2026, with completion targeted for May 31, 2027. The award funds research to develop small molecule therapeutics for heart failure by inhibiting tristetraprolin (TTP), a protein that regulates cardiac metabolism and inflammatory responses. The research...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded University of Massachusetts Medical School a $1.5 million Project Grant (CFDA 93.837, Cardiovascular Diseases Research) effective September 1, 2025, through June 30, 2030, to investigate perivascular adipose tissue (PVAT) as a protective factor against atherosclerotic cardiovascular disease. The research project directly addresses the leading cause of U.S. mortality by examining why certain arteries,...